产品
编 号：F741928
分子式：C23H27N7
分子量：401.51
分子式：C23H27N7
分子量：401.51
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1005307-86-7
产品详情
生物活性：
PR5-LL-CM01 is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50= 7.5 μM). Anti-tumor activies.
体内研究：
PR5-LL-CM01 (20mg/kg; i.p.; 3 times per week) displays significant anti-tumor effect.Animal Model:6-8 weeks old Male NSG mice (bearing PANC1 or HT29 cells)
Dosage:20 mg/kg (drug stock dissolved in 1:1 Cremophor:ethanol solution)
Administration:Intraperitoneally 3 times per week; 32 days (PANC1 model); 10 days (HT29 model)
Result:Led to significant tumor inhibition in both PANC1 and HT29 xenografted mice. Did not visibly affect the mice body weight.
体外研究：
PR5-LL-CM01 has a range of IC50 at 2-4 μM in PDAC cells (PANC1, MiaPaCa2 and AsPC1, and a range of IC50 at 10-11 μM in CRC cells (HT29, HCT116 and DLD1). PR5-LL-CM01 has higher efficacy to specifically inhibit cancer cells and demonstrated low toxicity in normal cells. PR5-LL-CM01 strongly inhibited colony forming ability in both PANC1 and HT29 cells.PR5-LL-CM01 inhibits NF-κB activation and its target gene expression in PDAC and CRC cells.PR5-LL-CM01 (0-15 μM) dramatically decreases TNFα and IL8 expression in both PANC1 and HT29 cells.
PR5-LL-CM01 is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50= 7.5 μM). Anti-tumor activies.
体内研究：
PR5-LL-CM01 (20mg/kg; i.p.; 3 times per week) displays significant anti-tumor effect.Animal Model:6-8 weeks old Male NSG mice (bearing PANC1 or HT29 cells)
Dosage:20 mg/kg (drug stock dissolved in 1:1 Cremophor:ethanol solution)
Administration:Intraperitoneally 3 times per week; 32 days (PANC1 model); 10 days (HT29 model)
Result:Led to significant tumor inhibition in both PANC1 and HT29 xenografted mice. Did not visibly affect the mice body weight.
体外研究：
PR5-LL-CM01 has a range of IC50 at 2-4 μM in PDAC cells (PANC1, MiaPaCa2 and AsPC1, and a range of IC50 at 10-11 μM in CRC cells (HT29, HCT116 and DLD1). PR5-LL-CM01 has higher efficacy to specifically inhibit cancer cells and demonstrated low toxicity in normal cells. PR5-LL-CM01 strongly inhibited colony forming ability in both PANC1 and HT29 cells.PR5-LL-CM01 inhibits NF-κB activation and its target gene expression in PDAC and CRC cells.PR5-LL-CM01 (0-15 μM) dramatically decreases TNFα and IL8 expression in both PANC1 and HT29 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备